Table 2.
Patients and tumor characteristics of TFE3(+) ccRCC and TFE3(−) ccRCC and comparison between them.
| ccRCC (n = 72) | TFE3(+) ccRCC (n = 24) | TFE3(−) ccRCC (n = 48) | P | |
|---|---|---|---|---|
| Age | 51.50 [42.75, 61.00] | 48.50 [39.50, 56.25] | 53.50 [45.00, 61.00] | 0.075 |
| Sex | 1.000 | |||
| Male | 46 (63.89) | 15 (62.50) | 31 (64.58) | |
| Female | 26 (36.11) | 9 (37.50) | 17 (35.42) | |
| BMI | 23.01 [21.65, 26.16] | 22.22 [21.65, 27.15] | 23.61 [21.82, 25.88] | 0.477 |
| Chief complaint | 0.255 | |||
| Examination | 47 (65.28) | 13 (54.17) | 34 (70.83) | |
| Symptom | 25 (34.72) | 11 (45.83) | 14 (29.17) | |
| Laterality | 0.677 | |||
| Left | 35 (48.61) | 13 (54.17) | 22 (45.83) | |
| Right | 37 (51.39) | 11 (45.83) | 26 (54.17) | |
| Diameter (cm) | 4.50 [2.88, 6.10] | 5.95 [4.00, 8.72] | 3.90 [2.77, 5.38] | 0.011 * |
| T | 0.335 | |||
| T1 | 55 (76.39) | 17 (70.83) | 38 (79.17) | |
| T2 | 8 (11.11) | 4 (16.67) | 4 (8.33) | |
| T3 | 8 (11.11) | 2 (8.33) | 6 (12.50) | |
| T4 | 1 (1.39) | 1 (4.17) | 0 (0.00) | |
| N | 0.203 | |||
| N0 | 68 (94.44) | 21 (87.50) | 47 (97.92) | |
| N1 | 4 (5.56) | 3 (12.50) | 1 (2.08) | |
| M | 0.333 | |||
| M0 | 71 (98.61) | 23 (95.83) | 48 (100.00) | |
| M1 | 1 (1.39) | 1 (4.17) | 0 (0.00) | |
| AJCC group | 0.488 | |||
| Stage I | 55 (76.39) | 17 (70.83) | 38 (79.17) | |
| Stage II | 7 (9.72) | 3 (12.50) | 4 (8.33) | |
| Stage III | 9 (12.50) | 3 (12.50) | 6 (12.50) | |
| Stage IV | 1 (1.39) | 1 (4.17) | 0 (0.00) | |
| WHO ISUP grade | 0.161 | |||
| G1 | 2 (3.08) | 0 (0.00) | 2 (4.17) | |
| G2 | 37 (56.92) | 7 (41.18) | 30 (62.50) | |
| G3 | 23 (35.38) | 8 (47.06) | 15 (31.25) | |
| G4 | 3 (4.62) | 2 (11.76) | 1 (2.08) | |
| Surgery | 0.140 | |||
| RN | 26 (36.11) | 12 (50.00) | 14 (29.17) | |
| nonRN | 46 (63.89) | 12 (50.00) | 34 (70.83) | |
| Drug therapy | 1.000 | |||
| Yes | 9 (13.24) | 3 (15.00) | 6 (12.50) | |
| No | 59 (86.76) | 17 (85.00) | 42 (87.50) | |
| NLR | 2.21 [1.66, 3.14] | 2.74 [2.13, 3.42] | 2.01 [1.59, 2.85] | 0.017 * |
| Scr | 80.50 [67.00, 94.25] | 81.50 [71.75, 90.25] | 80.50 [67.00, 96.25] | 0.820 |
| LVI | 1.000 | |||
| Yes | 6 (8.45) | 2 (8.70) | 4 (8.33) | |
| No | 65 (91.55) | 21 (91.30) | 44 (91.67) | |
| IHC_TFE3 | <0.001*** | |||
| + | 24 (33.33) | 24 (100.00) | 0 (0.00) | |
| - | 48 (66.67) | 0 (0.00) | 48 (100.00) | |
| Ki67 | 8.00 [3.00, 10.00] | 10.00 [5.00, 15.00] | 6.50 [3.00, 10.00] | 0.111 |
| Recurrence | 0.839 | |||
| Yes | 4 (5.71) | 2 (8.70) | 2 (4.26) | |
| No | 66 (94.69) | 21 (91.30) | 45 (95.74) | |
| Metastasis | 0.022* | |||
| Yes | 6 (8.57) | 5 (21.74) | 1 (2.13) | |
| No | 64 (91.43) | 18 (78.26) | 46 (97.87) | |
| Survival status | 0.325 | |||
| Alive | 65 (90.28) | 20 (83.33) | 45 (93.75) | |
| Dead | 7 (9.72) | 4 (16.67) | 3 (6.25) |
TFE3(+) ccRCC, ccRCC with positive TFE3 immunohistochemistry; TFE3(−) ccRCC, ccRCC with negative TFE3 immunohistochemistry; BMI, body mass index; AJCC, American Joint Committee on Cancer; WHO, World Health Organization; ISUP, International Society of Urological Pathology; RN, partial nephrectomy; NLR, neutrophil/lymphocyte ratio; Scr, serum creatinine; LVI, lymphovascular invasion; IHC, immunohistochemistry. *, 0.01 < P < 0.05; ***, P < 0.001.